Key Finding:
Biomarkers of immune checkpoint inhibitor response, like PD-L1 and tumor mutational burden, have low prevalence in uveal melanoma and are not associated with benefit from immune blockade.
Publications
Immune profiling of metastatic uveal melanoma and response to immune checkpoint inhibitors
– Caris Life Sciences
Download Publication